Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18–49 years of age - Ward, Brian J.; Séguin, Annie; Couillard, Julie; Trépanier, Sonia; Landry, Nathalie (Vaccine, 2021)
Keywords: Adult; Adults; Adverse events; Age; Allergy and Immunology; Antibodies; Antibodies, Viral; Antigens; blood; Cell culture; Cell-mediated immunity; Chronic illnesses; Combined vaccines; compliance; Confidence intervals; Consistency; demographic statistics; Demographics; Demography; Eggs; Evaluation; Female; females; Headaches; hemagglutination; Hemagglutination inhibition; Hemagglutination Inhibition Tests; Hemagglutinins; Humans; Immunization; Immunogenicity; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human - prevention & control; intramuscular injection; Lot-to-lot; Male; Mutation; Nicotiana benthamiana; Northern Hemisphere; Pain; Plant-derived quadrivalent influenza vaccine; Plants; Population studies; Proteins; Safety; Safety and immunogenicity; Seasons; Seroconversion; Strains (organisms); Trimers; vaccination; Vaccines; Vaccines, Combined; Vaccines, Inactivated; Virus-like particles; Viruses; Hong Kong China; California; Thailand; United States--US; Phuket Thailand; China; Nicotiana benthamiana; Safety and immunogenicity; Cell-mediated immunity; Plant-derived quadrivalent influenza vaccine; Lot-to-lot; Virus-like particles